Vet BE Guideline [Power / Sample Size]

posted by mittyri  – Russia, 2024-02-05 17:49 (850 d 03:34 ago) – Posting: # 23857
Views: 7,840

Hi Helmut and BEQool!

❝ ❝ France and Ireland - however, it was for veterinary product

❝ This might explain it. The last time I read the vet-GL it was crap (politely speaking).


That's interesting how CHMP EMA Guidelines invade CVMP Guidelines. I am trying to catch the logic:

For substances with highly variable disposition where it is difficult to show bioequivalence due to high intra-individual variability, different alternative designs have been suggested in the literature (e.g. replicate study design). A replicate cross-over study design using 3 periods (partial replication where only the reference product is replicated in all animals) or 4 periods (full replication, where each subject receives the test and reference products twice) can be carried out.
So CVMP people have some concerns about other designs we don't know yet.:-D

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
183 visitors (0 registered, 183 guests [including 34 identified bots]).
Forum time: 22:24 CEST (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5